您的位置: 首页 > 2015年3月 第46卷 第2期 > 文字全文
2023年7月 第38卷 第7期11
目录

I-IIa期宫颈鳞状细胞癌患者术后随诊和复发情况分析

Follow up and recurrance of patients with I-IIa stage cervical cancer after surgical treatment

来源期刊: 广州医药 | 30-31 发布时间:2021-11-30 收稿时间:2025/11/13 16:48:48 阅读量:13
作者:
关键词:
宫颈鳞状细胞癌随诊复发影响因素
Cervical cancerFollow-upRecurrenceAssociated factors
DOI:
10.3969/j.issn.1000-8535.2015.02.010
收稿时间:
2014-11-19 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 调查I-IIa期宫颈鳞状细胞癌患者术后随诊和复发情况,并探索随诊和复发的相关因素。方法 分析2011年1月—2012年6月中山市妇幼保健院收治的128例宫颈鳞状细胞癌患者的临床资料,分析他们的术后随诊情况及其影响因素。将有液基薄层细胞学(TCT)及盆腔检查者视为有效随诊的患者,分析肿瘤复发情况及其影响因素。结果 128例患者中,有效随诊104例(占总人数的81.25%)。年龄组越小,随诊率越高(P=0.034);城市患者较农村患者,随诊率高(P=0.028);文化程度越高,随诊率越高(P=0.028);职业为公务员、教师、公司职员或自由职业、个体,随诊率比职业为家庭妇女和工人更高(P=0.030)。在104例随诊者中,2年复发8例(占7.7%)。临床分期较晚,肿瘤直径>4cm,病理类型,脉管内瘤栓阳性,淋巴结转移阳性是影响患者2年复发的危险因素(P<0.05)。结论 临床分期,肿瘤直径,脉管内瘤栓阳性,淋巴结转移等临床病理特征与患者复发密切相关。应针对宫颈癌患者社会人口学特点制定措施,提高随诊率。
Objective To investigate the follow-up rate after surgical treatment and the recurrence rate among patients with cervical squamous cell carcinoma in I-IIa stage, and identify associated factors. Methods The clinical data of 128 cases of cervical squamous cell carcinoma from January 2011 to June 2012 in Zhongshan maternal and child health hospital was collected. Follow up record of these cases was analyzed and factors associated with follow up were identified. Patients having taken thinprep liquid-based cytology test (TCT) and pelvioscopy were treated as cases being followed effectively, and their recurrence and associated factors were analyzed. Results Among the 128 patients, 104(81.25%) were effectively followed. Patients with younger age(P=0.034), living in city (P=0.028), with higher education level(P=0.028) had higher follow-up rate. Civil servants, teachers and freelancers had higher follow-up rate than housewives and workers (P=0.030).Eight of the 104 effectively followed cases recurred within two years after surgery, accounting for 7.7%. The associated factors of recurrence included clinical stage, tumor diameter, larger than 4cm, the depth of myometrial invasion, deeper than 2/3, vascular tumor thrombus positive, and lymph node metastasis positive (P<0.05). Conclusion Clinical stage, tumor size, vascular tumor thrombus positive, lymph node metastasis positive were associated with recurrence. Tailored strategies should be developed to improve the follow up rate based on the social and demographic characteristics of patients.
1、 陈华,陈立云,尹宗兰. 宫颈癌患者介入治疗的护理[J]. 哈尔滨医药,2013,33(4):332-333. 陈华,陈立云,尹宗兰. 宫颈癌患者介入治疗的护理[J]. 哈尔滨医药,2013,33(4):332-333.
2、 桂金川,宋红梅,方向东,等. 不同剂量紫杉醇联合顺铂新辅助化疗局部晚期宫颈癌的疗效观察[J]. 哈尔滨医药,2013,33(2):89-90. 桂金川,宋红梅,方向东,等. 不同剂量紫杉醇联合顺铂新辅助化疗局部晚期宫颈癌的疗效观察[J]. 哈尔滨医药,2013,33(2):89-90.
3、 刘军防,尚延慧. 影响宫颈癌患者术后预后的相关因素分析[J]. 中国实用医刊,2013,40(4):78-80. 刘军防,尚延慧. 影响宫颈癌患者术后预后的相关因素分析[J]. 中国实用医刊,2013,40(4):78-80.
4、 叶元,尹茳平,李力. 宫颈癌手术治疗后复发的临床病理因素分析[J]. 实用妇产科杂志,2011,27(7):535-538. 叶元,尹茳平,李力. 宫颈癌手术治疗后复发的临床病理因素分析[J]. 实用妇产科杂志,2011,27(7):535-538.
5、 熊琼英,广怡,刘成. 宫颈癌新辅助化学疗法不同途径的疗效评价[J]. 现代妇产科进展,2012,21(1):55-57. 熊琼英,广怡,刘成. 宫颈癌新辅助化学疗法不同途径的疗效评价[J]. 现代妇产科进展,2012,21(1):55-57.
6、 廖震华,陈增春,陈桂. 190例宫颈癌患者临床病理特征及预后分析[J]. 中国肿瘤,2010,19(4):283-286. 廖震华,陈增春,陈桂. 190例宫颈癌患者临床病理特征及预后分析[J]. 中国肿瘤,2010,19(4):283-286.
7、 周艳秋,张礼婕,陈玉芬,等. 宫颈上皮内瘤样病变与宫颈癌患者随访档案的建立与管理[J]. 当代护士,2007(6):110-112. 周艳秋,张礼婕,陈玉芬,等. 宫颈上皮内瘤样病变与宫颈癌患者随访档案的建立与管理[J]. 当代护士,2007(6):110-112.
8、 戴志琴,潘凌亚,黄惠芳. 子宫颈上皮内瘤变Ⅲ级患者的术后随诊及其影响因素[J]. 中华妇产科杂志,2007,42(2):107-110. 戴志琴,潘凌亚,黄惠芳. 子宫颈上皮内瘤变Ⅲ级患者的术后随诊及其影响因素[J]. 中华妇产科杂志,2007,42(2):107-110.
9、 赵勤,王新萍,冯杏君. 宫颈上皮内瘤变患者术后随访的管理体会[J]. 海峡药学,2010,22(11):292-293. 赵勤,王新萍,冯杏君. 宫颈上皮内瘤变患者术后随访的管理体会[J]. 海峡药学,2010,22(11):292-293.
10、 王忠民,姜继勇,乔新民. 复发宫颈癌发病因素及其不同治疗方式对预后的影响[J]. 中国实用妇科与产科杂志,2010,2(3): 224-226. 王忠民,姜继勇,乔新民. 复发宫颈癌发病因素及其不同治疗方式对预后的影响[J]. 中国实用妇科与产科杂志,2010,2(3): 224-226.
11、 Goncalves A, Fabbro M, Lhomm éC, et al. A phase II trial to evaluate gefitinib as second or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer[J]. Gynecol Oncol, 2008, 108 (1): 42-46. Goncalves A, Fabbro M, Lhomm éC, et al. A phase II trial to evaluate gefitinib as second or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer[J]. Gynecol Oncol, 2008, 108 (1): 42-46.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录